Literature DB >> 20427553

Target validation: the Parkinson disease perspective.

David G Standaert, Talene A Yacoubian.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20427553     DOI： 10.1242/dmm.004192

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN： 1754-8403            Impact factor:   5.758


× No keyword cloud information.
  4 in total

Review 1.  Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.

Authors:  Fernando Calahorro; Manuel Ruiz-Rubio
Journal:  Invert Neurosci       Date:  2011-11-08

2.  Parkinson's disease, primates, and gene therapy: vive la différence?

Authors:  Travis B Lewis; David G Standaert
Journal:  Mov Disord       Date:  2010-12-17       Impact factor: 10.338

Review 3.  The bad, the good, and the ugly about oxidative stress.

Authors:  Marlene Jimenez-Del-Rio; Carlos Velez-Pardo
Journal:  Oxid Med Cell Longev       Date:  2012-04-26       Impact factor: 6.543

4.  Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.

Authors:  Xinru Li; Jenny Lee; Dee Parsons; Karen Janaurajs; David G Standaert
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.